PubMed:19207031 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCoin-sentences

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":103},"obj":"Sentence"},{"id":"T2","span":{"begin":104,"end":109},"obj":"Sentence"},{"id":"T3","span":{"begin":110,"end":288},"obj":"Sentence"},{"id":"T4","span":{"begin":289,"end":491},"obj":"Sentence"},{"id":"T5","span":{"begin":492,"end":613},"obj":"Sentence"},{"id":"T6","span":{"begin":614,"end":634},"obj":"Sentence"},{"id":"T7","span":{"begin":635,"end":1015},"obj":"Sentence"},{"id":"T8","span":{"begin":1016,"end":1131},"obj":"Sentence"},{"id":"T9","span":{"begin":1132,"end":1296},"obj":"Sentence"},{"id":"T10","span":{"begin":1297,"end":1305},"obj":"Sentence"},{"id":"T11","span":{"begin":1306,"end":1581},"obj":"Sentence"},{"id":"T12","span":{"begin":1582,"end":1686},"obj":"Sentence"},{"id":"T13","span":{"begin":1687,"end":1847},"obj":"Sentence"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-entities

LitCoin-SeqVar

{"project":"LitCoin-SeqVar","denotations":[{"id":"T1","span":{"begin":1317,"end":1326},"obj":"SequenceVariant"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-GeneOrGeneProduct-v2

LitCoin-GeneOrGeneProduct-v0

LitCoin-GeneOrGeneProduct-v3

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":78,"end":83},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":197,"end":202},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":261,"end":266},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":301,"end":306},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":533,"end":538},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":1112,"end":1117},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":1167,"end":1172},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":1189,"end":1194},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":1231,"end":1236},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1369,"end":1374},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1464,"end":1469},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1486,"end":1491},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":1500,"end":1505},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":1594,"end":1599},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1724,"end":1729},"obj":"GeneOrGeneProduct"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin_Mondo_095

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":789,"end":792},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1221,"end":1224},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":1375,"end":1378},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1492,"end":1495},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0017169"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0009833"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0009833"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0009833"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-MeSH-Disease-2

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":23,"end":47},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":469,"end":481},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":593,"end":605},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":878,"end":891},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":893,"end":896},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1682,"end":1685},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"DISEASE"},{"id":"A2","pred":"ID:","subj":"T2","obj":"DISEASE"},{"id":"A3","pred":"ID:","subj":"T3","obj":"DISEASE"},{"id":"A4","pred":"ID:","subj":"T4","obj":"DISEASE"},{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-NCBITaxon-2

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":482,"end":490},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":776,"end":784},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":789,"end":792},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":797,"end":802},"obj":"OrganismTaxon"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-MONDO_bioort2019

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":23,"end":47},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":469,"end":481},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":593,"end":605},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":878,"end":891},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":893,"end":896},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1682,"end":1685},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"#label","subj":"T1","obj":"DISEASE"},{"id":"A2","pred":"#label","subj":"T2","obj":"DISEASE"},{"id":"A3","pred":"#label","subj":"T3","obj":"DISEASE"},{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"},{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"},{"id":"A6","pred":"#label","subj":"T6","obj":"DISEASE"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-Chemical-MeSH-CHEBI

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":144,"end":152},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":153,"end":160},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":703,"end":711},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":712,"end":719},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":1221,"end":1224},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":1375,"end":1378},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":1492,"end":1495},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D003596"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_16040"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D000225"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_16708"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D003596"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_16040"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D000225"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_16708"},{"id":"A9","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_8984"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_8984"},{"id":"A11","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_8984"}],"text":"Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.\nAIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults.\nMATERIALS \u0026 METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype.\nRESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI.\nCONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment."}

LitCoin-training-merged